InnoCan Pharma
Herzliya
About InnoCan Pharma
Cannabinoids interact with the endocannabinoid receptor system, which is located throughout the body and plays an important role in many processes. InnoCan aims to harness the power of cannabinoids to target a wide variety of health problems. InnoCan plans to initially innovate new dermatology treatments, where research shows topical cannabinoid-combined treatments are highly effective.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: $10K – $50K
- Total funding: $17.6M
- Funding stage: IPO
- Last round: Post-IPO Debt (Mar 2026)
- Ticker: cnsx:INNO
- Website: innocanpharma.com
- Phone: +972.54.471.1171
Industries & Categories
Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/innocan-pharma-130804 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.